Abstract
The current guideline-recommended blood pressure values are difficult to maintain in general practice, partly due to the lack of ideal anti-hypertensive agents. Since morning hypertension has a high correlation with cardiovascular events, expectations that telmisartan, a long-acting angiotensin-II type-1 receptor blocker (ARB), can improve cardiovascular mortality are high. In this study, the efficiency of telmisartan in reducing morning hypertension and pulse wave velocity (PWV) as a practical surrogate endpoint was investigated. Seventeen unsupervised and 7 untreated hypertensive patients were prescribed telmisartan 40 mg/day for 3 months. Medication already prescribed upon enrollment in this study was continued, with the exception of ARBs (all of which turned out to be losartan 50 mg/day), which were discontinued and replaced with telmisartan. Morning home blood pressure (MHBP), office blood pressure (OBP), and brachial-ankle PWV (baPWV) were investigated in a prospective fashion. A stratified analysis was performed regarding previous use (group L) or non-use (group N) of losartan. Over a 3-month period, telmisartan was found to significantly reduce both OBP (from 153±13/85±9 to 141±17/80±7 mmHg (p
| Original language | English |
|---|---|
| Pages (from-to) | 545-550 |
| Number of pages | 6 |
| Journal | Hypertension Research |
| Volume | 27 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2004 |
Fingerprint
Keywords
- Angiotensin-II type-1 receptor blocker
- Ankle-brachial pressure index
- Arterial wall stiffness
- Losartan
- Uric acid
ASJC Scopus subject areas
- Internal Medicine
Cite this
Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. / Uchida, Haruhito Adam; Nakamura, Yoshio; Kaihara, Masanobu; Sugimoto, Taro; Norii, Hisanori; Sasaki, Motofumi; Sato, Hajime; Makino, Hirofumi.
In: Hypertension Research, Vol. 27, No. 8, 08.2004, p. 545-550.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension
AU - Uchida, Haruhito Adam
AU - Nakamura, Yoshio
AU - Kaihara, Masanobu
AU - Sugimoto, Taro
AU - Norii, Hisanori
AU - Sasaki, Motofumi
AU - Sato, Hajime
AU - Makino, Hirofumi
PY - 2004/8
Y1 - 2004/8
N2 - The current guideline-recommended blood pressure values are difficult to maintain in general practice, partly due to the lack of ideal anti-hypertensive agents. Since morning hypertension has a high correlation with cardiovascular events, expectations that telmisartan, a long-acting angiotensin-II type-1 receptor blocker (ARB), can improve cardiovascular mortality are high. In this study, the efficiency of telmisartan in reducing morning hypertension and pulse wave velocity (PWV) as a practical surrogate endpoint was investigated. Seventeen unsupervised and 7 untreated hypertensive patients were prescribed telmisartan 40 mg/day for 3 months. Medication already prescribed upon enrollment in this study was continued, with the exception of ARBs (all of which turned out to be losartan 50 mg/day), which were discontinued and replaced with telmisartan. Morning home blood pressure (MHBP), office blood pressure (OBP), and brachial-ankle PWV (baPWV) were investigated in a prospective fashion. A stratified analysis was performed regarding previous use (group L) or non-use (group N) of losartan. Over a 3-month period, telmisartan was found to significantly reduce both OBP (from 153±13/85±9 to 141±17/80±7 mmHg (p
AB - The current guideline-recommended blood pressure values are difficult to maintain in general practice, partly due to the lack of ideal anti-hypertensive agents. Since morning hypertension has a high correlation with cardiovascular events, expectations that telmisartan, a long-acting angiotensin-II type-1 receptor blocker (ARB), can improve cardiovascular mortality are high. In this study, the efficiency of telmisartan in reducing morning hypertension and pulse wave velocity (PWV) as a practical surrogate endpoint was investigated. Seventeen unsupervised and 7 untreated hypertensive patients were prescribed telmisartan 40 mg/day for 3 months. Medication already prescribed upon enrollment in this study was continued, with the exception of ARBs (all of which turned out to be losartan 50 mg/day), which were discontinued and replaced with telmisartan. Morning home blood pressure (MHBP), office blood pressure (OBP), and brachial-ankle PWV (baPWV) were investigated in a prospective fashion. A stratified analysis was performed regarding previous use (group L) or non-use (group N) of losartan. Over a 3-month period, telmisartan was found to significantly reduce both OBP (from 153±13/85±9 to 141±17/80±7 mmHg (p
KW - Angiotensin-II type-1 receptor blocker
KW - Ankle-brachial pressure index
KW - Arterial wall stiffness
KW - Losartan
KW - Uric acid
UR - http://www.scopus.com/inward/record.url?scp=5044235079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5044235079&partnerID=8YFLogxK
U2 - 10.1291/hypres.27.545
DO - 10.1291/hypres.27.545
M3 - Article
C2 - 15492473
AN - SCOPUS:5044235079
VL - 27
SP - 545
EP - 550
JO - Hypertension Research
JF - Hypertension Research
SN - 0916-9636
IS - 8
ER -